Starting Attruby (acoramidis) early and taking it continuously helps adults with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer, stay…
Articles by Margarida Maia, PhD
Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with…
Amvuttra (vutrisiran) was associated with improvements in quality of life and physical function in adults with transthyretin amyloidosis…
A rare mutation in the TTR gene — mutations in which are the cause of hereditary transthyretin amyloidosis (hATTR) —…
Six months of treatment with Amvuttra (vutrisiran) appears to maintain or slightly improve clinical status and quality of life…
Blood levels of the transthyretin (TTR) protein at the start of Vyndaqel (tafamidis) treatment and after one month may help…
Attruby (acoramidis) slows disease progression and significantly reduces death and cardiovascular-related hospitalizations in adults with hereditary or wild-type…
People with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer when the disease is diagnosed and treated earlier, with treatment benefits…
The number of people diagnosed with transthyretin amyloidosis (ATTR) in the U.S. is climbing, a surge researchers attribute to…
Adults who carry the Val30Met, or V30M, mutation — the most common cause of early-onset hereditary transthyretin amyloidosis with…